Purchase of a Seahorse Bioscience XF Analyzer
Wistar Institute, Philadelphia PA
Investigators
Linked publications, trials & patents
Abstract
PROJECT SUMMARY Support is requested for the purchase of a Seahorse XFe96 Bioanalyzer for researchers at The Wistar Institute in Philadelphia. The Seahorse XFe96 performs assays to quantify mitochondrial respiration, glycolytic activity, endogenous and exogenous fatty acid oxidation, substrate oxidation and metabolic phenotype. This request will facilitate to growing focus of Wistar researchers in cancer and immune metabolism. The Wistar Institute is the nation?s oldest biomedical research institute, with long-standing excellence in the fields of cancer research, vaccines and immunology. Ten users at all levels (Full, Associate and Assistant Professor) from all five programs (Gene Expression and Regulation;? Molecular and Cellular Oncogenesis;? Tumor Microenvironment and Metastasis;? Translational Tumor Immunology;? Vaccines) are included in this application. The users include such notable scientists as Dario Altieri (discoverer of survivin, pioneer of inhibitors of mitochondrial heat shock proteins), Hildegund Ertl (vaccine development), Dmitry Gabrilovich (discover of myeloid-derived suppressor cells), Meenhard Herlyn (etiology and therapy of melanoma), and Rugang Zhang (epigenetics of ovarian cancer). Also included is Zachary Schug, a newly-recruited metabolomics researcher who is expert with Seahorse technology. The PI is Maureen Murphy (the p53 tumor suppressor and metabolism). The ten combined researchers have long-standing interest and expertise in metabolism, as noted by numerous publications in this area, many of which are collaborative. The requested Seahorse XFe96 will be housed within the Proteomics and Metabolomics Facility at The Wistar Institute, and maintained and overseen by Dr. Hamid Baniasadi, an expert in metabolomics hired at the Institute over one year ago. This application lists over one third of all of the Investigators at Wistar, so the unit will be broadly used. There are currently no Seahorse Analyzers that are readily or easily accessible for Wistar Investigators. Preliminary data for this application comes from shared usage of three XF24 Analyzers on the campus of the University of Pennsylvania, all of which are over 0.5 miles or more from Wistar. All of these units are heavily utilized, older, and in frequent need of repair. Further, none of them are capable of performing the experiments outlined in this proposal, utilizing 3D spheroid cultures and high throughput drug screens. A detailed usage and support plan for the Seahorse XFe96 is included in this application, for which support is respectfully requested.
View original record on NIH RePORTER →